Compare Star Bulk Carriers Corp (SBLK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs TG Therapeutics Inc — how do they compare? Star Bulk Carriers Corp trades at $27.91 (market cap $3.09B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: TG Therapeutics Inc is far larger — about 2.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.79% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SBLK | TGTX | |
|---|---|---|
Market Cap | $3.09B | $7.64B |
Sector | Industrials | Health |
52-Week High | $29.15 | $59.06 |
52-Week Low | $16.79 | $26.94 |
Enterprise Value | $3.77B | $7.84B |
Dividend Yield | 6.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $27.89, down 1.86% on the day, amid a bullish technical signal and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.21 per share, beating estimates, with net income surging to $144.9 million. Valuation metrics appear attractive with a P/E of 10.85 and EV/EBITDA of 7.46, while profitability improved significantly with a net margin of 23.87% in 2026. Recent news highlights dividend declarations and strong operational results.
Outlook remains positive driven by earnings beats and healthy cash flow, though risks include dry bulk rate volatility and competitive pressures. Analyst consensus is bullish with 14 buy ratings, supporting potential upside, but investors should monitor shipping market cycles and debt levels.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
